Financhill
Sell
27

PRPH Quote, Financials, Valuation and Earnings

Last price:
$0.72
Seasonality move :
8.43%
Day range:
$0.67 - $0.75
52-week range:
$0.61 - $7.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.06x
P/B ratio:
0.46x
Volume:
352.9K
Avg. volume:
273.9K
1-year change:
-84.94%
Market cap:
$17.4M
Revenue:
$44.4M
EPS (TTM):
-$1.54

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRPH
ProPhase Labs
$5.9M -$0.24 -66.29% -3.33% --
APDN
Applied DNA Sciences
$1.2M -$0.33 15.3% -93.47% --
FONR
Fonar
-- -- -- -- --
OCX
OncoCyte
$101.7K -$0.37 -68.15% -65.42% $4.13
VCYT
Veracyte
$116.7M $0.26 18.83% -93.75% $43.22
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRPH
ProPhase Labs
$0.73 -- $17.4M -- $0.00 0% 1.06x
APDN
Applied DNA Sciences
$0.23 -- $11.9M -- $0.00 0% 0.26x
FONR
Fonar
$15.18 -- $97.1M 10.84x $0.00 0% 0.96x
OCX
OncoCyte
$2.29 $4.13 $38.6M -- $0.00 0% 34.81x
VCYT
Veracyte
$43.41 $43.22 $3.4B -- $0.00 0% 7.74x
XWEL
XWELL
$1.52 -- $8M -- $0.00 0% 0.20x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRPH
ProPhase Labs
31.06% -0.205 37.21% 1.12x
APDN
Applied DNA Sciences
-- 1.466 -- 2.83x
FONR
Fonar
0.05% 2.598 0.09% 9.32x
OCX
OncoCyte
-- 0.162 -- 0.39x
VCYT
Veracyte
-- 2.147 -- 4.59x
XWEL
XWELL
-- -0.924 -- 1.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRPH
ProPhase Labs
-$165K -$7.9M -47.22% -59.59% -252.29% -$4.2M
APDN
Applied DNA Sciences
$244.9K -$3.3M -116.43% -116.43% -402.32% -$3.6M
FONR
Fonar
$10M $4.6M 6.12% 6.13% 21.06% -$161K
OCX
OncoCyte
$50K -$6.4M -211.42% -211.42% -11706.09% -$5.6M
VCYT
Veracyte
$79M $12.7M -0.84% -0.84% 14.54% $27.7M
XWEL
XWELL
$2.1M -$4.6M -71.82% -71.82% -54.82% -$3.8M

ProPhase Labs vs. Competitors

  • Which has Higher Returns PRPH or APDN?

    Applied DNA Sciences has a net margin of -209.38% compared to ProPhase Labs's net margin of -405.45%. ProPhase Labs's return on equity of -59.59% beat Applied DNA Sciences's return on equity of -116.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    APDN
    Applied DNA Sciences
    30.12% -$0.32 $9M
  • What do Analysts Say About PRPH or APDN?

    ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2437.72%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 13057.9%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is PRPH or APDN More Risky?

    ProPhase Labs has a beta of -0.304, which suggesting that the stock is 130.392% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.397, suggesting its less volatile than the S&P 500 by 60.306%.

  • Which is a Better Dividend Stock PRPH or APDN?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or APDN?

    ProPhase Labs quarterly revenues are $3.1M, which are larger than Applied DNA Sciences quarterly revenues of $813.1K. ProPhase Labs's net income of -$6.6M is lower than Applied DNA Sciences's net income of -$3.3M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.06x versus 0.26x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    1.06x -- $3.1M -$6.6M
    APDN
    Applied DNA Sciences
    0.26x -- $813.1K -$3.3M
  • Which has Higher Returns PRPH or FONR?

    Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 12.56%. ProPhase Labs's return on equity of -59.59% beat Fonar's return on equity of 6.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    FONR
    Fonar
    40.24% $0.46 $158.9M
  • What do Analysts Say About PRPH or FONR?

    ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2437.72%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    FONR
    Fonar
    0 0 0
  • Is PRPH or FONR More Risky?

    ProPhase Labs has a beta of -0.304, which suggesting that the stock is 130.392% less volatile than S&P 500. In comparison Fonar has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.214%.

  • Which is a Better Dividend Stock PRPH or FONR?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or FONR?

    ProPhase Labs quarterly revenues are $3.1M, which are smaller than Fonar quarterly revenues of $25M. ProPhase Labs's net income of -$6.6M is lower than Fonar's net income of $3.1M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 10.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.06x versus 0.96x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    1.06x -- $3.1M -$6.6M
    FONR
    Fonar
    0.96x 10.84x $25M $3.1M
  • Which has Higher Returns PRPH or OCX?

    OncoCyte has a net margin of -209.38% compared to ProPhase Labs's net margin of -11733.04%. ProPhase Labs's return on equity of -59.59% beat OncoCyte's return on equity of -211.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    OCX
    OncoCyte
    43.48% -$0.98 $9.7M
  • What do Analysts Say About PRPH or OCX?

    ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2437.72%. On the other hand OncoCyte has an analysts' consensus of $4.13 which suggests that it could grow by 80.13%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    OCX
    OncoCyte
    0 2 0
  • Is PRPH or OCX More Risky?

    ProPhase Labs has a beta of -0.304, which suggesting that the stock is 130.392% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.313%.

  • Which is a Better Dividend Stock PRPH or OCX?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or OCX?

    ProPhase Labs quarterly revenues are $3.1M, which are larger than OncoCyte quarterly revenues of $115K. ProPhase Labs's net income of -$6.6M is higher than OncoCyte's net income of -$13.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.06x versus 34.81x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    1.06x -- $3.1M -$6.6M
    OCX
    OncoCyte
    34.81x -- $115K -$13.5M
  • Which has Higher Returns PRPH or VCYT?

    Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 13.08%. ProPhase Labs's return on equity of -59.59% beat Veracyte's return on equity of -0.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    VCYT
    Veracyte
    68.19% $0.19 $1.2B
  • What do Analysts Say About PRPH or VCYT?

    ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2437.72%. On the other hand Veracyte has an analysts' consensus of $43.22 which suggests that it could fall by -0.43%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    VCYT
    Veracyte
    6 2 1
  • Is PRPH or VCYT More Risky?

    ProPhase Labs has a beta of -0.304, which suggesting that the stock is 130.392% less volatile than S&P 500. In comparison Veracyte has a beta of 1.706, suggesting its more volatile than the S&P 500 by 70.591%.

  • Which is a Better Dividend Stock PRPH or VCYT?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or VCYT?

    ProPhase Labs quarterly revenues are $3.1M, which are smaller than Veracyte quarterly revenues of $115.9M. ProPhase Labs's net income of -$6.6M is lower than Veracyte's net income of $15.2M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.06x versus 7.74x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    1.06x -- $3.1M -$6.6M
    VCYT
    Veracyte
    7.74x -- $115.9M $15.2M
  • Which has Higher Returns PRPH or XWEL?

    XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -56.4%. ProPhase Labs's return on equity of -59.59% beat XWELL's return on equity of -71.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    XWEL
    XWELL
    24.38% -$0.99 $14.8M
  • What do Analysts Say About PRPH or XWEL?

    ProPhase Labs has a consensus price target of --, signalling upside risk potential of 2437.72%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 360.53%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    XWEL
    XWELL
    0 0 0
  • Is PRPH or XWEL More Risky?

    ProPhase Labs has a beta of -0.304, which suggesting that the stock is 130.392% less volatile than S&P 500. In comparison XWELL has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.765%.

  • Which is a Better Dividend Stock PRPH or XWEL?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or XWEL?

    ProPhase Labs quarterly revenues are $3.1M, which are smaller than XWELL quarterly revenues of $8.4M. ProPhase Labs's net income of -$6.6M is lower than XWELL's net income of -$4.8M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 1.06x versus 0.20x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    1.06x -- $3.1M -$6.6M
    XWEL
    XWELL
    0.20x -- $8.4M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is SCHD a Good ETF to Buy?
Is SCHD a Good ETF to Buy?

With around $65.7 billion in net assets, Schwab’s US Dividend…

Is NAIL a Good ETF to Buy?
Is NAIL a Good ETF to Buy?

If you’re thinking about buying the NAIL ETF, this article…

3 High Dividend Dow Jones Stocks
3 High Dividend Dow Jones Stocks

Thanks to surging stock prices over the past two years,…

Stock Ideas

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 125x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
57
NARI alert for Jan 8

Inari Medical [NARI] is up 22.25% over the past day.

Buy
69
UNF alert for Jan 8

UniFirst [UNF] is up 20.59% over the past day.

Sell
31
APOG alert for Jan 8

Apogee Enterprises [APOG] is down 19.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock